Author

M. J. Gorman

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 5 Biochemistry· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:host-pathogen & immune response· 5 Research Focus:drug response / drug discovery· 4 Assay:proteomics· 4 Organism:non-human primate· 3 Organism:human· 2 Approach:statistical model· 2 Research Focus:cell type annotation· 1

Frequent Co-Authors

G. Alter· 4 shared C. Atyeo· 3 shared S. Fischinger· 3 shared A. Zhu· 2 shared C.-L. Hsieh· 2 shared D. A. Lauffenburger· 2 shared D. Yuan· 2 shared K. Bowman· 2 shared

Activity by Year

2020-2023 · peak 5/yr

Co-Author Collaboration Network

10 top collaborators · 32 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersImmunology

G. Alter

Mutual co-authors in cluster

Author profile →

7 papers

Recent·Most cited

Comparison of insect and human cytochrome b561 proteins: Insights into candidate ferric reductases in insects

J. D. Holst, L. G. Murphy, M. J. Gorman, E. Ragan

This study compares insect and human cytochrome b561 proteins to identify potential ferric reductases in insects, revealing conserved residues and structural features associated with ferric ion reduction.

bioRxiv · Sep 1, 2023Biochemistry

Early cross-coronavirus reactive signatures of protective humoral immunity against COVID-19

P. Kaplonek, C. Wang, Y. Bartsch, S. Fischinger, M. J. Gorman, K. Bowman, J. Kang, D. Dayal, P. Martin, R. Nowak, C.-L. Hsieh, J. Feldman, B. Juelg, E. Nilles, E. R. Musk, , G. Alter

The paper profiles early humoral immune responses in COVID-19 patients, finding that survivors show rapid SARS-CoV-2-specific immunity linked to pre-existing OC43 immunity, while non-survivors have delayed and blunted responses.

bioRxiv · May 11, 2021 · PreprintImmunology

An intranasal vaccine durably protects against SARS-CoV-2 variants in mice

A. O. Hassan, S. Shrihari, M. J. Gorman, B. Ying, D. Yuan, S. Raju, R. E. Chen, I. P. Dmitriev, E. Kashentseva, L. J. Adams, P.-Y. Shi, D. H. Fremont, D. T. Curiel, G. Alter, M. S. Diamond

This study shows that an intranasal vaccine provides durable protection against SARS-CoV-2 variants in mice, including emerging strains like B.1.351 and B.1.1.28.

bioRxiv · May 8, 2021Microbiology

Vaccination with SARS-CoV-2 Spike Protein and AS03 Adjuvant Induces Rapid Anamnestic Antibodies in the Lung and Protects Against Virus Challenge in Nonhuman Primates

J. R. Francica, B. J. Flynn, K. E. Foulds, A. T. Noe, A. P. Werner, I. N. Morre, M. Gagne, T. S. Johnston, C. Tucker, R. L. Davis, B. Flach, S. O'Connell, S. F. Andrew, E. Lamb, D. R. Flebbe, , McDermott

This study shows that an AS03-adjuvanted SARS-CoV-2 spike protein vaccine induces strong antibody responses and protects nonhuman primates from viral challenge.

bioRxiv · Mar 2, 2021 · PreprintImmunology

Adjuvanting a subunit SARS-CoV-2 nanoparticle vaccine to induce protective immunity in non-human primates

P. S Arunachalam, A. C. Walls, N. Golden, C. Atyeo, S. Fischinger, C. Li, P. Aye, M. J. Navarro, L. Lai, V. V. Edara, K. Roltgen, K. Rogers, L. Shirreff, D. E. Ferrell, S. Wrenn, , Coffma

This study evaluates adjuvants for a subunit SARS-CoV-2 nanoparticle vaccine in non-human primates, showing durable neutralizing antibody responses and protection against infection.

bioRxiv · Feb 10, 2021 · PreprintImmunology

Collaboration between the Fab and Fc contribute to maximal protection against SARS-CoV-2 in nonhuman primates following NVX-CoV2373 subunit vaccine with Matrix-M™ vaccination

M. J. Gorman, N. Patel, M. Guebre-Xabier, A. Zhu, C. Atyeo, K. Pullen, C. Loos, Y. Goez-Gazi, R. Carrion, J.-H. Tian, D. Yuan, K. Bowman, B. Zhou, S. Maciejewski, M. McGrath, , G. Alter

This study shows that NVX-CoV2373 vaccine induces antibodies with both neutralizing and Fc-effector functions, which together provide maximal protection against SARS-CoV-2 in non-human primates.

bioRxiv · Feb 5, 2021 · PreprintImmunology

Integrated technology platform for accelerated discovery of antiviral antibody therapeutics

P. Gilchuk, R. G. Bombardi, J. H. Erasmus, Q. Tan, R. S. Nargi, C. Soto, P. Abbink, T. J. Suscovich, L. A. Dunellin, A. Khandhar, J. Archer, J. Liang, M. E. Fouch, E. Davidson, B. Doranz, , R. H. Carnahan

This study develops an integrated platform to rapidly discover and validate potent antiviral human monoclonal antibodies against Zika virus.

bioRxiv · May 12, 2020Immunology